GALT next SlS

$GALT might be one of the most overlooked biotech setups right now.
The FDA just gave GALT a clear path toward full approval with a single confirmatory Phase 3 trial. The science is different from the crowded FGF21/weight-loss space: belapectin targets galectin-3, a protein involved in fibrosis and disease progression.

The new EASL data strengthened the thesis, showing potential across fibrosis markers, liver stiffness, and disease progression. If validated in Phase 3, this could represent a genuinely new way to attack MASH cirrhosis.

And the stock setup?
High short interest + expensive borrow + tight float = squeeze play.
GALT is actively exploring strategic partnerships = partner play.

Late-stage biotech with differentiated science and Big Pharma hunting for MASH assets = buyout play.
FDA clarity. New mechanism. Strong EASL data. Shorts crowded. Partnership search underway.
$GALT could get very interesting, very fast.